D
Cryo-Cell International, Inc.
CCEL
$7.17
$0.14262.03%
D
Sell
3/6/2025Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to D from D- on 3/6/2025 due to a substantial increase in the efficiency index, solvency index and growth index.
Cryo-Cell International, Inc. (CCEL) was upgraded to D from D- on 3/6/2025 due to a substantial increase in the efficiency index, solvency index and growth index.
D
Sell
5/2/2024Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to D- from E+ on 5/2/2024 due to a noticeable increase in the volatility index and total return index.
Cryo-Cell International, Inc. (CCEL) was upgraded to D- from E+ on 5/2/2024 due to a noticeable increase in the volatility index and total return index.
E
Sell
4/17/2024Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to E+ from D on 4/17/2024 due to a major decline in the efficiency index, solvency index and growth index. Operating cash flow declined 110.67% from $3.34M to -$356.9, and total revenue declined 0.31% from $7.88M to $7.85M.
Cryo-Cell International, Inc. (CCEL) was downgraded to E+ from D on 4/17/2024 due to a major decline in the efficiency index, solvency index and growth index. Operating cash flow declined 110.67% from $3.34M to -$356.9, and total revenue declined 0.31% from $7.88M to $7.85M.
D
Sell
3/1/2024Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D from C- on 3/1/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.08 to -$1.3503, net income declined 1,744.14% from $680.6 to -$11.19M, and EBIT declined 415.8% from $1.28M to -$4.05M.
Cryo-Cell International, Inc. (CCEL) was downgraded to D from C- on 3/1/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.08 to -$1.3503, net income declined 1,744.14% from $680.6 to -$11.19M, and EBIT declined 415.8% from $1.28M to -$4.05M.
C
Hold
2/13/2024Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 2/13/2024 due to a noticeable decline in the volatility index, valuation index and growth index.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 2/13/2024 due to a noticeable decline in the volatility index, valuation index and growth index.
C
Hold
12/1/2023Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 12/1/2023 due to an increase in the volatility index and valuation index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 12/1/2023 due to an increase in the volatility index and valuation index.
C
Hold
11/16/2023Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 11/16/2023 due to a decline in the total return index, efficiency index and volatility index.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 11/16/2023 due to a decline in the total return index, efficiency index and volatility index.
C
Hold
8/17/2023Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 8/17/2023 due to an increase in the total return index, volatility index and efficiency index. Total capital increased 6.51% from $10.32M to $10.99M.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 8/17/2023 due to an increase in the total return index, volatility index and efficiency index. Total capital increased 6.51% from $10.32M to $10.99M.
C
Hold
6/27/2023Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 6/27/2023 due to an increase in the volatility index and total return index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 6/27/2023 due to an increase in the volatility index and total return index.
D
Sell
3/6/2023Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to D+ from D on 3/6/2023 due to a significant increase in the growth index and valuation index. Earnings per share increased from $0.0556 to $0.0984, and total revenue increased 1.08% from $7.68M to $7.76M.
Cryo-Cell International, Inc. (CCEL) was upgraded to D+ from D on 3/6/2023 due to a significant increase in the growth index and valuation index. Earnings per share increased from $0.0556 to $0.0984, and total revenue increased 1.08% from $7.68M to $7.76M.
D
Sell
2/27/2023Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D from D+ on 2/27/2023 due to a decline in the total return index and volatility index.
Cryo-Cell International, Inc. (CCEL) was downgraded to D from D+ on 2/27/2023 due to a decline in the total return index and volatility index.
D
Sell
2/10/2023Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to D+ from D on 2/10/2023 due to an increase in the valuation index and volatility index.
Cryo-Cell International, Inc. (CCEL) was upgraded to D+ from D on 2/10/2023 due to an increase in the valuation index and volatility index.
D
Sell
1/26/2023Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D from D+ on 1/26/2023 due to a significant decline in the solvency index, growth index and volatility index. The quick ratio declined from 0.51 to 0.35, and earnings per share declined from $0.07 to $0.0556.
Cryo-Cell International, Inc. (CCEL) was downgraded to D from D+ on 1/26/2023 due to a significant decline in the solvency index, growth index and volatility index. The quick ratio declined from 0.51 to 0.35, and earnings per share declined from $0.07 to $0.0556.
D
Sell
9/16/2022Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 9/16/2022 due to a decline in the valuation index and volatility index.
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 9/16/2022 due to a decline in the valuation index and volatility index.
C
Hold
8/30/2022Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 8/30/2022 due to an increase in the volatility index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 8/30/2022 due to an increase in the volatility index.
D
Sell
7/1/2022Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 7/1/2022 due to a noticeable decline in the total return index and volatility index.
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 7/1/2022 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/3/2022Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 5/3/2022 due to a decline in the total return index and volatility index.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 5/3/2022 due to a decline in the total return index and volatility index.
C
Hold
4/18/2022Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 4/18/2022 due to a major increase in the growth index, valuation index and solvency index. EBIT increased 235.14% from -$1M to $1.35M, earnings per share increased from -$0.0744 to $0.0976, and debt to equity declined from 0.53 to 0.34.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 4/18/2022 due to a major increase in the growth index, valuation index and solvency index. EBIT increased 235.14% from -$1M to $1.35M, earnings per share increased from -$0.0744 to $0.0976, and debt to equity declined from 0.53 to 0.34.
C
Hold
3/25/2022Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 3/25/2022 due to a significant decline in the growth index, valuation index and volatility index. EBIT declined 178.8% from $1.27M to -$1M, earnings per share declined from $0.1 to -$0.0744, and operating cash flow declined 19.03% from $2.06M to $1.67M.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 3/25/2022 due to a significant decline in the growth index, valuation index and volatility index. EBIT declined 178.8% from $1.27M to -$1M, earnings per share declined from $0.1 to -$0.0744, and operating cash flow declined 19.03% from $2.06M to $1.67M.
C
Hold
4/15/2020Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 4/15/2020 due to a substantial increase in the growth index, efficiency index and valuation index. Operating cash flow increased 118.18% from $1.2M to $2.62M, and total capital increased 34.85% from $2M to $2.7M.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 4/15/2020 due to a substantial increase in the growth index, efficiency index and valuation index. Operating cash flow increased 118.18% from $1.2M to $2.62M, and total capital increased 34.85% from $2M to $2.7M.
C
Hold
4/9/2020Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 4/9/2020 due to a large decline in the total return index, efficiency index and volatility index. Total capital declined 26.92% from $2.74M to $2M, and net income declined 24.3% from $1.12M to $845.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 4/9/2020 due to a large decline in the total return index, efficiency index and volatility index. Total capital declined 26.92% from $2.74M to $2M, and net income declined 24.3% from $1.12M to $845.
C
Hold
4/16/2019Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from D+ on 4/16/2019 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 111.72% from $844 to $1.79M.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from D+ on 4/16/2019 due to a significant increase in the efficiency index, valuation index and growth index. Operating cash flow increased 111.72% from $844 to $1.79M.
D
Sell
1/18/2019Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to D+ from D on 1/18/2019 due to an increase in the total return index and volatility index.
Cryo-Cell International, Inc. (CCEL) was upgraded to D+ from D on 1/18/2019 due to an increase in the total return index and volatility index.
D
Sell
12/26/2018Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D from D+ on 12/26/2018 due to a decline in the volatility index and total return index.
Cryo-Cell International, Inc. (CCEL) was downgraded to D from D+ on 12/26/2018 due to a decline in the volatility index and total return index.
D
Sell
10/16/2018Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 10/16/2018 due to a large decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.07 to $0.03, net income declined 54.59% from $539.5 to $245, and EBIT declined 19.97% from $1.15M to $920.1.
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 10/16/2018 due to a large decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.07 to $0.03, net income declined 54.59% from $539.5 to $245, and EBIT declined 19.97% from $1.15M to $920.1.
C
Hold
10/8/2018Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 10/8/2018 due to a decline in the total return index.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 10/8/2018 due to a decline in the total return index.
C
Hold
7/24/2018Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 7/24/2018 due to a large increase in the total return index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 7/24/2018 due to a large increase in the total return index.
C
Hold
7/17/2018Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 7/17/2018 due to a large increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.36 to $0.07, EBIT increased 16.47% from $987.1 to $1.15M, and total revenue increased 4.78% from $6.23M to $6.53M.
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 7/17/2018 due to a large increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.36 to $0.07, EBIT increased 16.47% from $987.1 to $1.15M, and total revenue increased 4.78% from $6.23M to $6.53M.
D
Sell
5/2/2018Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 5/2/2018 due to a decline in the volatility index and solvency index.
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 5/2/2018 due to a decline in the volatility index and solvency index.
C
Hold
4/17/2018Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 4/17/2018 due to a major increase in the efficiency index and solvency index. The quick ratio increased from 0.85 to 0.94.
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 4/17/2018 due to a major increase in the efficiency index and solvency index. The quick ratio increased from 0.85 to 0.94.
D
Sell
4/12/2018Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 4/12/2018 due to a significant decline in the total return index, volatility index and growth index. EBIT declined 14.23% from $1.45M to $1.25M, and total revenue declined 6.1% from $6.9M to $6.48M.
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C- on 4/12/2018 due to a significant decline in the total return index, volatility index and growth index. EBIT declined 14.23% from $1.45M to $1.25M, and total revenue declined 6.1% from $6.9M to $6.48M.
C
Hold
1/22/2018Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 1/22/2018 due to a noticeable increase in the volatility index, total return index and solvency index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C- from D+ on 1/22/2018 due to a noticeable increase in the volatility index, total return index and solvency index.
D
Sell
10/17/2017Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C on 10/17/2017 due to a major decline in the efficiency index, total return index and solvency index. Debt to equity increased from -0.62 to -0.58, and total capital declined 4.41% from -$5.4M to -$5.64M.
Cryo-Cell International, Inc. (CCEL) was downgraded to D+ from C on 10/17/2017 due to a major decline in the efficiency index, total return index and solvency index. Debt to equity increased from -0.62 to -0.58, and total capital declined 4.41% from -$5.4M to -$5.64M.
C
Hold
10/18/2016Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from D on 10/18/2016 due to a significant increase in the total return index and efficiency index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from D on 10/18/2016 due to a significant increase in the total return index and efficiency index.
D
Sell
3/11/2016Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Earnings per share declined from $0.8 to -$0.0242, and EBIT declined 65.67% from $1.29M to $441.6.
Cryo-Cell International, Inc. (CCEL) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Earnings per share declined from $0.8 to -$0.0242, and EBIT declined 65.67% from $1.29M to $441.6.
C
Hold
10/16/2015Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 10/16/2015 due to a significant decline in the efficiency index and solvency index. Total capital declined 66.55% from -$10.7M to -$3.58M, and the quick ratio declined from 0.89 to 0.7.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 10/16/2015 due to a significant decline in the efficiency index and solvency index. Total capital declined 66.55% from -$10.7M to -$3.58M, and the quick ratio declined from 0.89 to 0.7.
C
Hold
7/16/2015Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C from C+ on 7/16/2015 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0291 to $0.02, net income declined 26.62% from $286.2 to $210, and EBIT declined 3.69% from $625.2 to $602.1.
Cryo-Cell International, Inc. (CCEL) was downgraded to C from C+ on 7/16/2015 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0291 to $0.02, net income declined 26.62% from $286.2 to $210, and EBIT declined 3.69% from $625.2 to $602.1.
C
Hold
7/2/2015Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C+ from C on 7/2/2015 due to a noticeable increase in the growth index, valuation index and solvency index. EBIT increased 237.22% from $185.4 to $625.2, operating cash flow increased 35.34% from $243.1 to $329, and the quick ratio increased from 0.82 to 0.9.
Cryo-Cell International, Inc. (CCEL) was upgraded to C+ from C on 7/2/2015 due to a noticeable increase in the growth index, valuation index and solvency index. EBIT increased 237.22% from $185.4 to $625.2, operating cash flow increased 35.34% from $243.1 to $329, and the quick ratio increased from 0.82 to 0.9.
C
Hold
1/2/2015Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C from C+ on 1/2/2015 due to a large decline in the volatility index and total return index.
Cryo-Cell International, Inc. (CCEL) was downgraded to C from C+ on 1/2/2015 due to a large decline in the volatility index and total return index.
C
Hold
10/16/2014Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C+ from C on 10/16/2014 due to a noticeable increase in the growth index, total return index and solvency index. Operating cash flow increased 102.77% from $468.5 to $950, and total revenue increased 0.92% from $4.89M to $4.94M.
Cryo-Cell International, Inc. (CCEL) was upgraded to C+ from C on 10/16/2014 due to a noticeable increase in the growth index, total return index and solvency index. Operating cash flow increased 102.77% from $468.5 to $950, and total revenue increased 0.92% from $4.89M to $4.94M.
C
Hold
9/4/2014Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C from C+ on 9/4/2014 due to a decline in the valuation index.
Cryo-Cell International, Inc. (CCEL) was downgraded to C from C+ on 9/4/2014 due to a decline in the valuation index.
C
Hold
7/7/2014Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C+ from C on 7/7/2014 due to a substantial increase in the volatility index, valuation index and total return index.
Cryo-Cell International, Inc. (CCEL) was upgraded to C+ from C on 7/7/2014 due to a substantial increase in the volatility index, valuation index and total return index.
C
Hold
5/5/2014Upgraded
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 5/5/2014 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.74 to 0.81.
Cryo-Cell International, Inc. (CCEL) was upgraded to C from C- on 5/5/2014 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.74 to 0.81.
C
Hold
2/28/2014Downgrade
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 2/28/2014 due to a noticeable decline in efficiency, growth and valuation. Earnings per share declined from $0.018 to -$0.0178, net income declined 186.06% from $194.4 to -$167.3, and operating cash flow declined 91.12% from -$245.6 to -$21.8.
Cryo-Cell International, Inc. (CCEL) was downgraded to C- from C on 2/28/2014 due to a noticeable decline in efficiency, growth and valuation. Earnings per share declined from $0.018 to -$0.0178, net income declined 186.06% from $194.4 to -$167.3, and operating cash flow declined 91.12% from -$245.6 to -$21.8.
AMEX
03/07/2025 1:01PM Eastern
Quotes delayed
